Scott Gottlieb has been joining boards both large and small. (Joins Pfizer board; here.)
In a Linked In blog, he announced he has joined the board of startup AETION, which is created to help pharma and others build and manage RWE.
in February 2019, AETION raised $27M from Sanofi, McKesson, and others. Total funding > $70M.
See a 2019 Aetion funding announcement here:
See Aetion website here: https://www.aetion.com/
Some trade press this summer on Aetion here. Partnership with Horizon, here. FDA, Brigham, and Aetion, here. (Syapse also announced a link with FDA; here.).
Some trade press this summer on Aetion here. Partnership with Horizon, here. FDA, Brigham, and Aetion, here. (Syapse also announced a link with FDA; here.).
Gottlieb blog at Linked In:
The health care system is enabling more effective ways to leverage electronic tools to gather and use vast amounts of health-related data. These tools offer new opportunities to use data collected during the routine care of patients to advance healthcare delivery, and to improve the development of new medical innovations. The supporting science and technology have advanced to a point where we can quickly and reliably analyze real-world data to generate evidence, and ultimately, make better health care decisions.
That’s why I’m delighted to be joining the Board of Directors at Aetion, a health care technology company that delivers real-world evidence for life sciences companies, payers, and other stakeholders. More efficient and effective application of evidence derived from practical settings can improve health care delivery, lower its cost, and make the development of new treatments more efficient. My work with Aetion will allow me to continue to advance goals I’ve championed over many years, in private and public roles.
Aetion is at the forefront of many important efforts in this burgeoning field. As one example, the company is working with Brigham and Women’s Hospital to help inform the use of RWE in drug development through the RCT DUPLICATE demonstration project. Brigham and Women’s Hospital researchers are running RWE studies in the Aetion platform to attempt to replicate the results of 30 completed randomized controlled trials, and to predict the results of seven ongoing Phase IV trials.
As part of this effort, researchers recently analyzed claims data via the Aetion Evidence Platform to predict the findings of the CAROLINA clinical trial. The real-world data analyses took 16 weeks. They reached the same conclusion as the 43-country, eight-year clinical trial. This study joins a growing body of evidence that demonstrates the potential for RWE in supporting post-market safety and efficacy studies.
This work is a recognition that new approaches and new technologies can expand the evidence we use, bring clinical research closer to more settings of care, and help inform better and faster decisions. RWE can complement and contextualize how we understand clinical interventions — answering not just do they work, but how they best work, and for which people. I’m thrilled to advise Aetion as we advance these opportunities for patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.